Table 4 The change of the volume, expenditures, and DDDc of each “4 + 7” List antihypertensive drug in the pre- and post-“4 + 7” periods
Volume (million DDD) | Expenditures (million CNY) | DDDc (CNY) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Pre- | Post- | GR (%) | Pre- | Post- | GR (%) | Pre- | Post- | GR (%) | |
Amlodipine | 11790.55 | 26305.12 | 123.10 | 39505.03 | 15424.75 | -60.95 | 3.35 | 0.59 | -82.50 |
Irbesartan | 6017.09 | 9736.77 | 61.82 | 15173.01 | 7709.53 | -49.19 | 2.52 | 0.79 | -68.60 |
Irbesartan hydrochlorothiazide | 1909.19 | 3899.69 | 104.26 | 6639.64 | 5545.92 | -16.47 | 3.48 | 1.42 | -59.11 |
Fosinopril | 572.97 | 657.15 | 14.69 | 3081.37 | 1531.17 | -50.31 | 5.38 | 2.33 | -56.67 |
Lisinopril | 0.00 | 6.02 | - | 0.00 | 2.77 | - | - | 0.46 | - |
Losartan | 3339.10 | 4749.23 | 42.23 | 8872.47 | 5702.14 | -35.73 | 2.66 | 1.20 | -54.81 |
Enalapril | 900.38 | 1780.08 | 97.70 | 540.23 | 1523.16 | 181.95 | 0.60 | 0.86 | 42.61 |
Total | 24529.28 | 47134.07 | 92.15 | 73811.75 | 37439.44 | -49.28 | 3.01 | 0.79 | -73.60 |